Empagliflozin for No-reflow Phenomenon in PCI for STEMI

Summary

Myocardial infarction remains, in our current era, a leading cause of morbidity and mortality both domestically and globally. A significant contributor to this issue is reperfusion injury, which enlarges the infarction, deteriorates ventricular function, leads to poorer outcomes, and currently has no specific treatment. Originally developed as an antidiabetic, empagliflozin has shown significant benefits in other organs and systems. Recent years have seen the demonstration of its cellular and vascular effects in animal models, potentially contributing to the reduction of reperfusion damage. However, no human studies have yet confirmed these effects. Consequently, this randomized, parallel-arm clinical trial was designed to evaluate the effect of empagliflozin treatment, administered from the pre-intervention period through to 3 days post-intervention, on the incidence of the no-reflow phenomenon in patients with ST-segment elevation myocardial infarction (STEMI) undergoing coronary angioplasty compared to a placebo. Before entering the hemodynamics room, participants in the intervention group will receive a loading dose of 25 mg of empagliflozin or a standar treatment. In-hospital treatment will continue with 10 mg empagliflozin daily for 3 days for the intervention group. Patients will be monitored weekly during the first month and bi-weekly during the second and third months. The primary outcome will be the incidence of the no-reflow phenomenon, measured through the Thrombolysis in Myocardial infarction (TIMI) flow scale in the coronary angiography performed to treat the infarction. Secondary outcomes will include the reduction of ST segment on the electrocardiogram, troponin levels, differences in the longitudinal strain by echocardiogram, and infarct size by magnetic resonance imaging.

Eligibility

Inclusion Criteria:

* Acute myocardial infarction with ST-segment elevation
* Presentation to the institute within 12 hours of symptom onset
* Coronary angioplasty chosen as the reperfusion treatment for the subject
* Known diagnosis of diabetes or admission glucose \>180 mg/dl.
* Informed consent signed

Exclusion Criteria:

* Hemodynamically unstable subjects
* Subjects undergoing thrombolysis treatment in the current event
* History of coronary revascularization surgery
* Known allergy or hypersensitivity to Sodium-glucose co-transporter-2 (SGLT2) inhibitors
* History of recurrent urinary tract infections
* Known chronic kidney disease and estimated glomerular filtration rate (eGFR) \< 20
* Ongoing treatment with any SGLT2 inhibitor
* Participation in another clinical trial or having participated in the week prior to recruitment
* For women of childbearing age: Current or planned pregnancy or lactation.

Conditions3

Interventions2

Related trials

• A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record — Herlev and Gentofte Hospital
• Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function. — Central Hospital, Nancy, France
• Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes — University Medical Centre Ljubljana
• Effect of Empagliflozin on Quality of Life in Chronic Heart Failure Patients With Diabetes Mellitus Type II — Fazaia Ruth Pfau Medical College
• Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension — China National Center for Cardiovascular Diseases
• Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines — Maria Sklodowska-Curie National Research Institute of Oncology
• The EMPA-FIT Study — Seoul National University Bundang Hospital
• The Role of SGLT2i in Management of Moderate AS — University of East Anglia

Browse More Trials